Iterum Therapeutics ((ITRM)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Iterum Therapeutics is launching a Phase 1 clinical trial titled ‘A Phase 1, Multi-Center, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Sulopenem Etzadroxil + Probenecid in Adolescent Patients With Bacterial Infection.’ The study aims to assess the safety, tolerability, and pharmacokinetics of the drug combination in adolescents with bacterial infections.
The intervention involves a single oral dose of 500 mg sulopenem etzadroxil and 500 mg probenecid, designed to enhance the treatment of bacterial infections in adolescents.
This interventional study is open-label with a single-group assignment, focusing on treatment as its primary purpose. There is no masking involved in the study design.
The study is set to begin on July 22, 2025, with the last update also recorded on the same date. These dates are crucial as they mark the initiation of the trial and the most recent update, indicating the study’s current status.
This trial could potentially influence Iterum Therapeutics’ stock performance by showcasing their commitment to expanding treatment options for bacterial infections. The outcome may also impact investor sentiment positively if the results are favorable, especially in comparison to competitors in the antibiotic market.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.